Sanofi (NYSE:SNY) said at the start of April that it promoted Bill Sibold to exec VP of Sanofi Genzyme, effective July 1, 2017. Sibold succeeds Dr. David Meeker, who is slated to leave the company at the end of June.
Sibold is the head of Sanofi Genzyme’s global multiple sclerosis, oncology and immunology organization. He led the company in preparation for the global launches of Dupilumab and Sarilumab. He joined Sanofi in 2011 as head of the MS business.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!